Posts Feed
Comments Feed

« Math Could Help Cure LeukemiaNew PLAVIX(R) (clopidogrel) 300mg Loading Dose Tablet Now Available For Use In ACS (acute Coronary Syndrome) Patients »

UCB’s VimpatTM Recommended For Approval In Europe For Epilepsy

Jun 30th 2008Drug InformationEpilepsy

Regulated information UCB announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending that the European Commission grants a marketing authorisation for lacosamide, proposed trade name Vimpat?, for the adjunctive treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy, aged 16 years and older.

More: continued here

No Comments »

Trackback URI | Comments RSS

Leave a Reply

You must be logged in to post a comment.

« Number Of People With Diabetes Increases To 24 MillionNew England Journal Of Medicine Publishes Results From Two Of The Landmark Phase III RECORD Studies With Rivaroxaban »

UCB’s Vimpat(TM) Recommended For Approval In Europe For Epilepsy

Jun 30th 2008Drug InformationEpilepsy

UCB announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMEA) has issued a positive opinion recommending that the European Commission grants a marketing authorisation for lacosamide, proposed trade name Vimpat(TM), for the adjunctive treatment of partial onset seizures with or without secondary generalisation in patients with epilepsy, aged 16 years and older.

More: continued here

No Comments »

Trackback URI | Comments RSS

Leave a Reply

You must be logged in to post a comment.

1